白蛋白结合配体[177Lu]Lu-PSMA-ALB-56在mCRPC患者中的单剂生物分布与剂量学
该药耐受良好,无严重不良事件,血循环时间延长,48小时肿瘤摄取最高;肿瘤归一化吸收剂量达6.64±6.92 Gy/GBq,较已发表的其他治疗性PSMA配体数据最高高2.3倍,唾液腺剂量相似,但肾脏和红骨髓剂量增加。
要点
- [177Lu]Lu-PSMA-ALB-56单剂耐受良好,未观察到严重不良事件。
- 肿瘤归一化吸收剂量为6.64±6.92 Gy/GBq,较已发表的其他治疗性PSMA配体数据最高高2.3倍。
- 肾脏和红骨髓归一化吸收剂量分别为2.54±0.94和0.29±0.07 Gy/GBq,均较对照配体增加。
核心结论
- 白蛋白结合型PSMA放射性配体的概念在临床可行,并能提高肿瘤吸收剂量。
- 经进一步优化配体设计后,可能改善前列腺癌患者的治疗结局。
研究设计与样本
- 患者接受单剂[177Lu]Lu-PSMA-ALB-56 3360±393 MBq(120-160 μg),随后7天行全身SPECT/CT显像。
- 在SPECT/CT图像上勾画健康组织与肿瘤病灶的感兴趣体积进行剂量学评估,并通过血液生物标志物评估安全性与疗效。
主要发现
- [177Lu]Lu-PSMA-ALB-56耐受良好,未观察到严重不良事件。
- SPECT显示[177Lu]Lu-PSMA-ALB-56在血中循环时间延长,注射后48小时肿瘤病灶摄取最高。
- 肿瘤归一化吸收剂量为6.64±6.92 Gy/GBq,较已发表的其他治疗性PSMA配体(如PSMA-617和PSMA I&T)数据最高高2.3倍。
- 唾液腺归一化吸收剂量为0.87±0.43 Gy/GBq,与已发表的其他治疗性PSMA配体数据相似。
- 肾脏和红骨髓归一化吸收剂量分别为2.54±0.94 Gy/GBq和0.29±0.07 Gy/GBq,均增加。
临床怎么用
- 该单剂剂量学数据支持白蛋白结合型PSMA配体可提高肿瘤吸收剂量,但肾脏与红骨髓剂量增加,需在后续研究中关注器官剂量约束。
局限性
- 仅评估单剂给药后的生物分布与剂量学,未报告重复给药或长期疗效数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for metastatic, castration-resistant prostate cancer (mCRPC). Recently, the concept of modifying PSMA radioligands with an albumin-binding entity was demonstrated as a promising measure to increase the tumor uptake in preclinical experiments. The aim of this study was to translate the concept to a clinical setting and evaluate the safety and dosimetry of [177Lu]Lu-PSMA-ALB-56, a novel PSMA radioligand with albumin-binding properties. METHODS: Ten patients (71.8 ± 8.2 years) with mCRPC received an activity of 3360 ± 393 MBq (120-160 μg) [177Lu]Lu-PSMA-ALB-56 followed by whole-body SPECT/CT imaging over 7 days. Volumes of interest were defined on the SPECT/CT images for dosimetric evaluation for healthy tissue and tumor lesions. General safety and therapeutic efficacy were assessed by measuring blood biomarkers. RESULTS: [177Lu]Lu-PSMA-ALB-56 was well tolerated, and no severe adverse events were observed. SPECT images revealed longer circulation of [177Lu]Lu-PSMA-ALB-56 in the blood with the highest uptake in tumor lesions at 48 h post injection. Compared with published data for other therapeutic PSMA radioligands (e.g. PSMA-617 and PSMA I&T), normalized absorbed doses of [177Lu]Lu-PSMA-ALB-56 were up to 2.3-fold higher in tumor lesions (6.64 ± 6.92 Gy/GBq) and similar in salivary glands (0.87 ± 0.43 Gy/GBq). Doses to the kidneys and red marrow (2.54 ± 0.94 Gy/GBq and 0.29 ± 0.07 Gy/GBq, respectively) were increased. CONCLUSION: Our data demonstrated that the concept of albumin-binding PSMA-radioligands is feasible and leads to increased tumor doses. After further optimization of the ligand design, the therapeutic outcomes may be improved for patients with prostate cancer.
引用
- Kramer V, Fernández R, Lehnert W, et al. Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC. Eur J Nucl Med Mol Imaging. 2020. PMID: 32949253. doi:10.1007/s00259-020-05022-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。